NAD+

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that occupies a central place in cellular metabolism. It functions in two distinct ways; as a critical carrier in reduction-oxidation reactions, shuttling electrons to drive energy production, and as a consumable cosubstrate for enzymes including the sirtuins, the poly(ADP-ribose) polymerases (PARPs), and the CD38 and CD157 ectoenzymes that regulate metabolism, circadian rhythm, and DNA repair ^[1][2].

A defining observation of the field is that cellular NAD+ concentrations decline during normal aging, and also with obesity and hypertension, contributing to defects in nuclear and mitochondrial function that underlie many age-associated pathologies ^[1][2]. This has motivated intense interest in raising NAD+ through its precursors, most prominently nicotinamide mononucleotide (NMN) and nicotinamide riboside, whose availability can be rate-limiting for NAD+ biosynthesis ^[2]. Preclinical models show that replenishing NAD+ can extend healthspan, counteract metabolic syndrome, and improve a range of cardiac and neurodegenerative conditions ^[4].

Human clinical evidence has grown alongside the animal literature. A randomized, double-blind, placebo-controlled trial found that twelve weeks of oral NMN at 250 mg per day was well tolerated, elevated NAD+ metabolism as reflected by higher serum nicotinamide, and showed a tendency toward reduced arterial stiffness in healthy middle-aged adults ^[3]. Another randomized trial reported that NMN increased skeletal muscle insulin sensitivity and insulin signaling in prediabetic, overweight or obese postmenopausal women ^[5]. Mechanistic studies continue to link NAD+ to vascular and brain aging; for example, NMN supplementation rescued aging-associated blood-brain barrier leakage through an endothelial CX43-PARP1-NAD+ pathway in mice ^[6].

NAD+ itself and its precursors are sold widely as dietary supplements in oral forms, and clinics also offer intravenous NAD+ protocols. Foundational reviews frame NAD+ repletion as a promising therapeutic opportunity for aging and its associated disorders, while noting that optimal dosing and long-term outcomes remain active questions ^[1][4].

Oral NAD+ and its precursors are well tolerated in trials, with flushing, nausea or mild gastrointestinal upset at higher intakes. Intravenous NAD+ is a different proposition, and the discomfort tracks the infusion rate rather than the dose alone.

In a retrospective review of four consecutive daily 500 mg infusions in a commercial setting, NAD+ produced moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure that resolved when the infusion ended, and took 97 minutes on average to give against 37 minutes for the same dose of nicotinamide riboside; ALT, AST, hsCRP, BUN and creatinine and TSH did not change over 30 days, and alkaline phosphatase fell in the NAD+ arm while staying inside the reference range ^[26]. That is a chart review from a wellness clinic rather than a controlled trial, and it is close to the entire published human safety record for infused NAD+. Long-term safety of sustained high-dose supplementation, by any route, is not established.

NAD+ is one of the oldest known coenzymes, first identified in 1906 by the British biochemists Arthur Harden and William Young, who called the heat-stable fermentation cofactor cozymase. Over the following decades its structure and function were resolved by Hans von Euler-Chelpin, who worked out its composition, and by Otto Warburg, who showed that the nicotinamide portion is the part that accepts and carries hydride during metabolism. This body of work was foundational enough to be recognized with Nobel Prizes, including awards to Harden and von Euler-Chelpin in 1929 and to Warburg in 1931. In the modern era, the discovery that NAD+ is consumed as a substrate by sirtuins, PARPs, and CD38, and that its levels decline with age, transformed a classic textbook coenzyme into a central target of metabolic and longevity science.

NAD+ enjoys a rare double reputation as both a settled piece of classical biochemistry and a frontier of aging research. Because every living cell depends on it for energy metabolism, its importance is beyond dispute, which gives NAD+ restoration strategies a credibility that many supplements lack. Interest surged once researchers linked declining NAD+ pools to the sirtuin and PARP systems that govern DNA repair and metabolism, framing its decline as an Achilles heel of aging cells. Human studies of precursors such as NMN have reported measurable increases in NAD+ metabolites alongside favorable trends in vascular and insulin-related measures, which sustains enthusiasm. Balanced discussion acknowledges that subjective benefits reported by users are less well characterized than the underlying biochemistry, and that optimal dosing and long-term outcomes remain active questions.